Nuveen
IMNM icon

Nuveen’s Immunome IMNM Stock Holding History

Nuveen’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.12M Sell
288,922
-16,332
-5% -$349K ﹤0.01% 1979
2026
Q1 		$6.68M Buy
305,254
+135,908
+80% +$3.02M ﹤0.01% 1766
2025
Q4 		$3.64M Buy
169,346
+24,002
+17% +$421K ﹤0.01% 2050
2025
Q3 		$1.7M Sell
145,344
-96,066
-40% -$956K ﹤0.01% 2363
2025
Q2 		$2.25M Buy
241,410
+1,470
+0.6% +$12.1K ﹤0.01% 2252
2025
Q1 		$1.61M Buy
239,940
+53,853
+29% +$517K ﹤0.01% 2426
2024
Q4 		$1.98M Sell
186,087
-2,931
-2% -$35.4K ﹤0.01% 2395
2024
Q3 		$2.76M Sell
189,018
-110,272
-37% -$1.57M ﹤0.01% 2266
2024
Q2 		$3.62M Buy
+299,290
New +$4.68M ﹤0.01% 2101

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Nuveen's IMNM Position: Q2 2026 in Review

Nuveen reduced its Immunome (IMNM) stake by 5.4% in Q2 2026, selling an estimated $349K and leaving 288,922 shares worth $6.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1979.

Nuveen first reported a position in IMNM in Q2 2024 and has held it in 9 quarters since. The position peaked at $6.68M in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Nuveen held 288,922 shares of Immunome worth $6.12M as of Q2 2026.
  • Nuveen sold 16,332 Immunome shares in Q2 2026, an estimated $349K.
  • Immunome made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1979 holding.
  • Nuveen first reported a position in Immunome in Q2 2024 and has held it in 9 quarters since.
  • Nuveen's Immunome position peaked at $6.68M in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.